The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• Angiogenesis, or blood vessel development, is vital in both normal physiology and diseases like cancer.
• Multimerin 2 (MMRN2), an extracellular matrix (ECM) protein secreted by endothelial cells (ECs), inhibits angiogenesis by binding pro-angiogenic factors like VEGFA.
• The regulation of angiogenesis involves complex interactions between cytokines, EC receptors, and ECM components.

Purpose of the Study:

• To investigate the regulation and function of Multimerin 2 (MMRN2) in angiogenesis.
• To explore the role of matrix metalloproteinases (MMPs) in MMRN2 processing and its impact on EC behavior.
• To assess the potential of MMRN2 as a biomarker in tumor-associated angiogenesis.

Main Methods:

• Analysis of MMRN2 mRNA levels under angiogenic stimuli.
• Enzymatic assays to determine MMRN2 processing by MMP-2 and MMP-9.
• In vitro studies on EC migration and pseudopodia formation, with and without MMP inhibitors.
• Immunofluorescence staining of tumor sections to examine MMP-9 and MMRN2 co-localization.

Main Results:

• MMRN2 mRNA levels decrease significantly during angiogenic stimuli.
• MMRN2 is proteolytically cleaved by MMP-9 and MMP-2, which correlates with increased EC migration.
• Down-regulation of MMRN2 enhances EC pseudopodia formation, an effect reversed by MMP-9 inhibitors.
• MMRN2 is remodeled in tumor angiogenesis, showing co-localization with MMP-9 in tumor sections.

Conclusions:

• MMRN2 plays a critical role in regulating endothelial cell function and sprouting angiogenesis.
• Proteolytic processing of MMRN2 by MMPs facilitates EC migration, contributing to angiogenesis.
• Altered MMRN2 expression in tumors suggests its potential as a biomarker for predicting treatment efficacy in angiogenesis-related conditions.